Introduction
Seemingly random fluctuations in lung function have previously been shown to be associated with acute exacerbations in asthma (1, 2). One utilised measurement is peak expiratory flow (PEF), which has been used to develop the composite endpoint CompEx, allowing for shorter clinical trials in which exacerbations have previously been the primary endpoint (3). Understanding how measures of fluctuations in lung function are associated with CompEx risk may further increase the efficiency of clinical trials.
Objectives
⦁ Study the association between variation in PEF and CompEx risk.
⦁ Evaluate the use of a frailty parameter to account for population heterogeneity in CompEx risk.